NOSOTROS:
Vifor Pharma skip to main content Home About Who We Are Global Presence Collaborations & Business Partnerships Management Congresses & Events Corporate Governance Transparency R&D Investigator Initiated Studies History Data Privacy Our expertise Iron Deficiency Nephrology Cardio-Renal Products Iron Phosphate Binder Potassium Binder Infectious Disease / OTX Investors Half-Year Results 2020 Share Information Share Analyst Coverage Consensus Estimate Dividends and Tax Value Form 8937 Financial Calendar Conferences and Roadshows Reporting Centre Corporate Reports Presentations for Investors Shareholder Information Employee Share Ownership Webcasts Annual General Meeting Shareholder Contact Disclosure of Shareholdings Investor Contact Media Half-Year Results 2020 Press Releases Download Library Media Contact Responsibility Our Approach COVID-19 Integrity Patients Patients Stories Employees Environment Community Iron Deficiency Day Career Our People Blog Contact and FAQs About Who We Are Global Presence Collaborations & Business Partnerships Management Congresses & Events Corporate Governance Transparency R&D Investigator Initiated Studies History Data Privacy Our expertise Iron Deficiency Nephrology Cardio-Renal Products Iron Phosphate Binder Potassium Binder Infectious Disease / OTX Investors Half-Year Results 2020 Share Information Share Analyst Coverage Consensus Estimate Dividends and Tax Value Form 8937 Financial Calendar Conferences and Roadshows Reporting Centre Corporate Reports Presentations for Investors Shareholder Information Employee Share Ownership Webcasts Annual General Meeting Shareholder Contact Disclosure of Shareholdings Investor Contact Media Half-Year Results 2020 Press Releases Download Library Media Contact Responsibility Our Approach COVID-19 Integrity Patients Patients Stories Employees Environment Community Iron Deficiency Day Career Our People Blog Contact and FAQs .
Iron Iron Deficiency and Iron Deficiency Anaemia Pipeline:Beta-Thalassemia
Nephrology Iron Deficiency and Iron Deficiency Anaemia Hyperkalaemia Hyperphosphatemia Diabetic Kidney Disease Pipeline Anaemia in Chronic Kidney Disease ANCA-Associated Vasculitis Chronic Kidney Disease - associated pruritus Secondary Hyperparathiroidism
Cardio-renal Iron Deficiency and Iron Deficiency Anaemia Hyperkalaemia
Products Brand Ferinject® Maltofer® Venofer® Mircera® Retacrit® Veltassa® Velphoro® Invokana®
Pipeline Avacopan Difelikefalin Rayaldee® Vadadustat VIT-2763 Iron NephrologyCardio-renalProducts-brandPipelineIronIron Deficiency and Iron Deficiency Anaemia Pipeline:Beta-Thalassemia Nephrology Iron Deficiency and Iron Deficiency Anaemia Hyperkalaemia Hyperphosphatemia Diabetic Kidney Disease Pipeline Cardio-renalIron Deficiency and Iron Deficiency Anaemia Hyperkalaemia Products Brand Ferinject® Maltofer® Venofer® Mircera® Retacrit® Veltassa® Velphoro® Invokana® Pipeline Avacopan Difelikefalin Rayaldee® Vadadustat VIT-2763 Pipeline Anaemia in Chronic Kidney Disease ANCA-Associated Vasculitis Chronic Kidney Disease - associated pruritus Secondary Hyperparathiroidism EN DEFR
Country Selector Vifor Pharma Global Australia Austria France Germany Romania Spain Switzerland Singapore United Kingdom PortugalSweden/Nordics
Vifor Pharma and Cara Therapeutics sign US license agreement for i.v. Korsuva™* to treat dialysis patients with pruritus Press release
OUR IRON DEFICIENCY PATIENTS
At Vifor Pharma, we put our patients at the centre of everything we do. With our expertise in iron metabolism, we aim to provide meaningful support to patients with iron deficiency by engaging directly with them and learning how to develop solutions that will make a difference. Read our Patients Stories
OUR NEPHROLOGY PATIENTS
At Vifor Pharma, we put our patients at the centre of everything we do. With our expertise in Nephrology, we aim to help patients with chronic kidney disease by engaging directly with them to understand their burden and needs and develop solutions that will make a difference. Read our Patients Stories
OUR CARDIO-RENAL PATIENTS
At Vifor Pharma, we put our patients at the centre of everything we do. With our expertise in Nephrology and Cardio, we want to address the unmet need in the cardio-renal field and support our patients by engaging directly with them and develop solutions that will make a difference. Read our Patients Stories
Corporate Responsibility
We are proud to launch our latest Corporate Responsibility Report, which shows examples of how Vifor Pharma lives the five pillars of Corporate Responsibility through various activities and measures in our sites and affiliates around the world. READ MORE PRESS RELEASE OUR IRON DEFICIENCY PATIENTS OUR NEPHROLOGY PATIENTS OUR CARDIO-RENAL PATIENTS CORPORATE RESPONSIBILITY Our therapeutic areas
We are a global leader in iron deficiency and iron deficiency anaemia therapies, with a history dating back to 1872, when pharmacist Caspar Friedrich Hausmann opened a pharmacy in St. Gallen, Switzerland. Building on our history in the treatment of iron deficiency, we have used our expertise in research and development, in-licensing, manufacturing, regulatory affairs and commercialisation to expand into the complementary fields of nephrology and cardio-renal therapies. IRON DEFICIENCY
With our iron deficiency and iron deficiency anaemia expertise in heart failure, kidney disease, gastroenterology or inflammatory bowel disease, patient blood management and woman’s health, we help patients affected by these conditions to live better, healthier lives. READ MORENEPHROLOGY
We offer patients a wide range of products and solutions across a number of conditions related to impaired renal function –anaemia in CKD, mineral and bone disease, kidney function preservation and improvement, and conditions associated with kidney impairment and its treatment. READ MORECARDIO-RENAL
Heart and kidneys are key organs with a clear connection, as patients suffering from heart failure can develop kidney disease and vice versa. With our expertise in nephrology and cardio, we address the unmet need in the field of cardio-renal, set new standards of care and help patients around the world lead better, healthier lives. READ MORE WORKING AT VIFOR PHARMA
Together we are making a difference: Finding new solutions, delivering high-quality products, driving scientific excellence and helping people around the world. READ MORE PRESS RELEASES Vifor Pharma and Cara Therapeutics sign US license agreement for i.v. Korsuva™* to treat dialysis patients with pruritus
20.10.2020 Vifor Pharma announces outcome of AFFIRM-AHF topline data
24.09.2020 Vifor Pharma Group announces successful sale of OM Pharma
18.09.2020 Vifor Pharma appoints Gregory Oakes as President North America and member of the Executive Committee
01.09.2020 Vifor Pharma Group reports continued growth in H1 2020
06.08.2020 VFMCRP PRESS RELEASE PHASE-II LUMINA-1 TRIAL OF CCX140
18.05.2020 VIFOR PHARMA PRESS RELEASE 92ND AGM
14.05.2020 VIFOR PHARMA PRESS RELEASE AKEBIA THERAPEUTICS GLOBAL PHASE-III PROGRAM RESULTS OF VADADUSTAT
05.05.2020 VIFOR PHARMA PRESS RELEASE PHASE-III KALM-2 TRIAL OF KORSUVA
21.04.2020 VIFOR PHARMA PRESS RELEASE UPDATE ON 92ND AGM
31.03.2020 VIFOR PHARMA PRESS RELEASE STRONG GROWTH IN 2019 AND RAISED GUIDANCE
12.03.2020 VIFOR PHARMA PRESS RELEASE SECOND INVESTMENT GRADE RATING FROM FITCH RATINGS
03.03.2020 VIFOR PHARMA PRESS RELEASE FRESENIUS KABI JOINT VENTURE IN CHINA
20.02.2020 VIFOR PHARMA PRESS RELEASE ACQUIRES PRIORITY REVIEW VOUCHER
17.02.2020 VIFOR PHARMA PRESS RELEASE IRON DEFICIENCY DAY 2019
26.11.2019 VFMCRP PRESS RELEASE PHASE-III ADVOCATE TRIAL OF AVACOPAN
26.11.2019 VIFOR PHARMA PRESS RELEASE LEE HEESON APPOINTED PRESIDENT INTERNATIONAL AND EC MEMBER
18.11.2019 VIFOR PHARMA PRESS RELEASE JOINT VENTURE WITH EVOTEC IN DEVELOPMENT IN NEPHROLOGY
06.11.2019 VIFOR PHARMA PRESS RELEASE COMMERCIAL COLLABORATION IN THE US WITH JANSSEN
04.11.2019 VIFOR PHARMA PRESS RELEASE APPOINTMENT OF NEW CHIEF MEDICAL OFFICER AND EC CHANGES
11.09.2019 VIFOR PHARMA PRESS RELEASE SP CREDIT RATING
09.09.2019 VIFOR PHARMA PRESS RELEASE H1 2019 RESULTS AND FULL-YEAR GUIDANCE
08.08.2019 VIFOR PHARMA PRESS RELEASE PIONEERING PROJECT VIFOR PHARMA AND THE UNIVERSITY OF BASEL
26.05.2019 VIFOR PHARMA PRESS RELEASE FIRST PATIENT TREATED IN DIAMOND STUDY
21.05.2019 VIFOR PHARMA PRESS RELEASE PHASE II AMBER STUDY
10.05.2019 VIFOR PHARMA PRESS RELEASE 91ST ANNUAL SHAREHOLDER MEETING
08.05.2019 VIFOR PHARMA PRESS RELEASE AKEBIA THERAPEUTICS EXPANSION OF LICENCE AGREEMENT
09.04.2019 VIFOR PHARMA PRESS RELEASE REPORTS STRONG 2018 RESULTS AND RAISED GUIDANCE
14.03.2019 VIFOR PHARMA PRESS RELEASE CHEMOCENTRYX CMA WITHDRAWAL AAV
24.01.2019 VIFOR PHARMA PRESS RELEASE UPDATED ON ANALYSIS OF VENOFER IN HIGH DOSAGE STUDY
22.01.2019 VIFOR PHARMA PRESS RELEASE POSITIVE PHASE-I TRIAL RESULTS FOR ORAL FERROPORTIN INHIBITOR
07.01.2019 VIFOR PHARMA PRESS RELEASE PATRICK TREANOR APPOINTED PRESIDENT OF RELYPSA AND EC MEMBER
12.12.2018 VIFOR PHARMA PRESS RELEASE 2018 IRON DEFICIENCY DAY
26.11.2018 Third Global Iron Deficiency Day to Raise Awareness of the Symptoms of Iron Deficiency
23.11.2017 Vifor Pharma Expands Exclusive License Agreement for The Commercialisation of Mircera® in the US
27.09.2017 Vifor Pharma Reports Strong H1 2017 Results and Raises Guidance
08.08.2017 European Commission Approves Marketing Authorisation for Veltassa®
21.07.2017 New Expert Review in the American Journal of Hematology Seeks to Change the Way We Test, Treat and Talk About Iron Deficiency in Chronic Inflammatory Conditions
18.07.2017 Vifor Pharma Announces Three Outcomes Trials in Heart Failure and Iron Deficiency
12.07.2017 Kissei to Market Avacopan in Japan for Vifor Fresenius Medical Care Renal Pharma
09.06.2017 Chmp Recommends Veltassa® for the Treatment of Hyperkalaemia in the EU
19.05.2017 Vifor Pharma and Akebia Announce Exclusive License Agreement to Provide Vadadustat to Fresenius Medical Care in the U.S. Upon FDA Approval
16.05.2017 89th Annual General Meeting of Galenica Ltd.
11.05.2017 Galenica Santé IPO – Full exercise of over-allotment option
12.04.2017 Successful Galenica Santé IPO, Galenica Group becomes Vifor Pharma Group
07.04.2017 IPO Galenica Santé: Galenica announces narrowed price range and upsizing of the IPO
03.04.2017 Advance information IPO of Galenica Santé
24.03.2017 Galenica launches IPO of Galenica Santé and sets price range
24.03.2017 COMCO ruling against HCI Solutions Ltd.
21.03.2017 Galenica announces plans for IPO of Galenica Santé on SIX Swiss Exchange
14.03.2017 Board of Directors launches “Milestone 2020” strategy plan: Galenica Group to become Vifor Pharma Group and float Galenica Santé on the stock exchange
14.03.2017 Results of the Galenica Group 2016
14.03.2017 Galenica Santé adds Merfen® and Vita-Merfen® to its OTC product portfolio
22.02.2017 Vifor Pharma Continues Commitment to Raise Awareness of Iron Deficiency
20.02.2017 Vifor Pharma and ChemoCentryx Announce Expansion of Avacopan Agreement for Rare Renal Diseases
14.02.2017 Planned division of the Galenica Group
19.01.2017 2016 sales of the Galenica Group
19.01.2017 The Galenica Group is taking over SD wholesaler Pharmapool
11.01.2017 Change to the shareholder structure of the Galenica Group
09.01.2017 Vifor Pharma and ChemoCentryx announce expansion of Kidney Health Alliance
23.12.2016 Vifor Pharma and ChemoCentryx announce expansion of Kidney Health Alliance to include CCX140 to treat renal diseases
23.12.2016 Swisscom Health to take over Galenica practice information system
09.12.2016 EFFECT-HF demonstrates a significantly beneficial effect of Ferinject® on exercise capacity among patients with chronic heart failure and iron deficiency – confirms findings of previous studies
07.12.2016 FDA Approves Supplemental New Drug Application for Veltassa® Removing Boxed Warning Regarding Drug-Drug Interactions
28.11.2016 Vifor Pharma leads initiatives to raise awareness of Iron Deficiency – 2nd Global Iron Deficiency Day on November 26, 2016
24.11.2016 Swissmedic approves ALOXI® for use in the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Children in Switzerland
25.10.2016 New management at Vifor Pharma and new Galenica Group CFO designated
06.10.2016 Galenica completes acquisition of Relypsa
02.09.2016 Galenica announces Expiration of Cash Tender Offer for Relypsa
01.09.2016 Galenica Group half year results 2016
09.08.2016 Galenica commences Tender Offer for Relypsa
04.08.2016 Galenica to acquire Relypsa to strengthen its Business unit Vifor Pharma
21.07.2016 Vifor Pharma to license commercialisation rights to Pfizer’s proposed biosimilar, Retacrit™, in the field of nephrology in the US
24.05.2016 Vifor Pharma strengthens company management – division of Galenica to take place once the new management is in place
24.05.2016 ESC guidelines strongly recommend Ferinject® as a treatment for iron deficiency in systolic heart failure patients
23.05.2016 The Galenica Group plans to take over SD wholesaler Pharmapool
20.05.2016 Change to the shareholder structure of the Galenica Group
11.05.2016 Vifor Pharma appoints Colin Bond as Chief Financial Officer
10.05.2016 Vifor Pharma licenses marketing rights to CCX168 in certain territories
10.05.2016 Vifor Fresenius Medical Care Renal Pharma acquires marketing rights to RAYALDEE®
09.05.2016 2016 Annual General Meeting of Galenica Ltd.
28.04.2016 Patiromer submitted to EMA to seek approval in the EU
25.04.2016 Results of the Galenica Group 2015
15.03.2016 2015 sales of the Galenica Group
21.01.2016 Swissmedic approves Akynzeo® (netupitant/palonosetron) for use in the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Switzerland
15.12.2015 Division of the Galenica Group planned for the 4th quarter of 2016
01.12.2015 SFI acquires Potters and the Equazen™ brand portfolio from Vifor Pharma
22.10.2015 Kissei receives Japanese approval for P-TOL® (in the USA and Europe commercialized as Velphoro®)
30.09.2015 Meta-analysis links Ferinject® treatment of iron deficiency to reduced rate for cardiovascular hospitalisations and deaths in systolic heart failure patients
31.08.2015 Vifor Fresenius Medical Care Renal Pharma and Relypsa Enter into Partnership to Commercialize Patiromer Fos in Europe and Additional Territories
11.08.2015 Vifor Fresenius Medical Care Renal Pharma enters into partnership with Relypsa to commercialise Patiromer FOS
11.08.2015 Galenica Group half-year results 2015
11.08.2015 Galenica Santé: new strategic priorities and changes to the organisational structure
03.07.2015 Galenica and Roche enter into exclusive license agreement for the commercialisation of Mircera® in the US
28.05.2015 Vifor Fresenius Medical Care Renal Pharma to expand its business activities
28.05.2015 2015 Annual General Meeting of Galenica Ltd.
07.05.2015 Measures to ensure strategy implementation
13.04.2015 Results of the Galenica Group for 2014
10.03.2015 Velphoro® receives Swissmedic approval
27.01.2015 Galenica Group sales 2014
21.01.2015 Velphoro® receives EU Marketing Authorisation
27.08.2014 Results of the Galenica Group for the first half of 2014
12.08.2014 Galenica lays foundation for two listed, independent companies
12.08.2014 Velphoro® (PA21) receives Positive CHMP Opinion
27.06.2014 2014 Annual General Meeting of Galenica
08.05.2014 Results of the Galenica Group for 2013
11.03.2014 Galenica Group sales 2013
21.01.2014
MORE NEWS Financial Calendar
03
March
Full-year results 2020
MORE DATES REPORTS
Download Half-year Report 2020 - Full Version (PDF) SHARE PRICE
Detailed information LinkedIn Twitter Youtube Sign up for our email alert services Terms and Conditions Legal Notice Terms of Use Privacy Policy Cookie Policy Vifor Pharma Management Ltd.
Flughofstrasse 61
P.O. Box
8152 Glattbrugg
Switzerland
+41 58 851 80 00 Map
